Alzheimer Biomarkers Higher in Women
Researchers identify sex-specific differences in amyloid, tau, and brain structure during the seventh decade of life.
By
Kathryn Wighton
January 30, 2026
Clinical Scorecard: Alzheimer Biomarkers Higher in Women
At a Glance
Category Detail
Condition Alzheimer Disease Pathology Key Mechanisms Higher amyloid and tau burden in women, influenced by apolipoprotein E epsilon 4 carrier status. Target Population Adults aged 60 to 69 years, with a focus on women. Care Setting Community-based cohort study.
Key Highlights
Women exhibit greater amyloid and tau pathology than men. Cortical thickness in women shows resilience against Alzheimer disease. Study included a diverse cohort with significant Hispanic and Black representation. Findings suggest sex differences in tau burden are pronounced in epsilon 4 carriers. No significant interactions observed between sex and age or race. Guideline-Based Recommendations
Diagnosis
Utilize amyloid and tau PET imaging for assessing Alzheimer pathology. Management
Consider sex and apolipoprotein E epsilon 4 status in treatment planning. Monitoring & Follow-up
Regular neuroimaging assessments to track amyloid and tau levels. Risks
Potential misclassification due to self-reported sex and unmeasured sociocultural factors. Patient & Prescribing Data
Adults aged 60 to 69 years, predominantly women.
Higher amyloid and tau levels in women may necessitate tailored therapeutic approaches.
Clinical Best Practices
Incorporate demographic factors in Alzheimer disease assessments. Conduct larger, balanced studies to explore intersectionality in Alzheimer outcomes. References
